Intravitreal Bevacizumab for Treatment of Uveitic Macular Edema

Ophthalmology

Volumn 114, Issue 8, 2007, Pages

  Cordero Coma, Miguel ^a,b   Sobrin, Lucia ^a   Onal, Sumru ^a   Christen, William ^c   Foster, C Stephen ^a  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b HOSPITAL DE LEÓN   (Spain)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHLORAMBUCIL; CYCLOSPORIN; DACLIZUMAB; INFLIXIMAB; METHOTREXATE; MOXIFLOXACIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; POVIDONE IODINE; TETRACAINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INFLAMMATION; INTRAOCULAR PRESSURE; KAPLAN MEIER METHOD; MALE; MEAN RETINAL THICKNESS; OPTICAL COHERENCE TOMOGRAPHY; PARAMETER; PRIORITY JOURNAL; RETINA; RETINA FOVEA; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; TREATMENT OUTCOME; UVEA; UVEITIS; VISUAL ACUITY;

EID: 34250199569     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.11.028     Document Type: Article

References (23)

1. Rothova A., Suttorp-van Schulten M.S., Frits Treffers W., and Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80 (1996) 332-336
2. Irvine S.R. A newly defined vitreous syndrome following cataract surgery. Am J Ophthalmol 36 (1953) 499-619
3. Rosenbaum J.T. Characterization of uveitis associated with spondyloarthritis. J Rheumatol 16 (1989) 792-796
4. Bayen H., Bayen M.C., De Curzon H.P., et al. Involvement of the posterior eye segment in HLA B27(+) iridocyclitis: incidence; value of surgical treatment. [in French]. J Fr Ophtalmol 11 (1988) 561-566
5. Markomichelakis N.N., Halkiadakis I., Pantelia E., et al. Patterns of macular edema in patients with uveitis. Qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 111 (2004) 946-953
6. Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol 97 (1999) 297-309
7. Frank R.N. Vascular diseases of the retina. In: Tso M.O. (Ed). Retinal Diseases: Biomedical Foundations and Clinical Management (1988), Lippincott, Philadelphia 138-164
8. Arend O., Remky A., Harris A., et al. Macular microcirculation in cystoid maculopathy of diabetic patients. Br J Ophthalmol 79 (1995) 628-632
9. Papadaki T., Zacharopoulos I., Iaccheri B., et al. Somatostatin for uveitic cystoid macular edema (CME). Ocul Immunol Inflamm 13 (2005) 469-470
10. Michels S., Rosenfeld P.J., Puliafito C.A., et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twelve-week results of an uncontrolled open label clinical study. Ophthalmology 112 (2005) 1035-1047
11. Nguyen Q.D., Shah S., Tatlipinar, et al. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. [letter]. Br J Ophthalmol 89 (2005) 1368-1370
12. Van Wijngaarden P., Coster D.J., and Williams K.A. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 293 (2005) 1509-1513
13. U.S. Food and Drug Administration. Medwatch. Barron H, Genentech. Important drug warning [letter]. Available at: http://www.fda.gov/medwatch/SAFETY/2005/Avastin_dearhcp.pdf. Accessed October 10, 2005.
14. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005) 331-335
15. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
16. Rosenfeld P.J., Fung A.E., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retina vein occlusion. Ophthalmic Surg Lasers Imaging 36 (2005) 336-339
17. Gutman F.A., and Zegarra H. Macular edema secondary to occlusion of the retinal veins. Surv Ophthalmol 28 suppl (1984) 462-470
18. Fleisher L.N., Ferrell J.B., and McGahan M.C. Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin. Inflammation 14 (1990) 325-335
19. Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 10 (2002) 239-246
20. Fine H.F., Baffi J., Reed G.F., et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 132 (2001) 794-796
21. Aiello L.P. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 29 (1997) 354-362
22. Manzano R.P., Peyman G.A., Khan P., and Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26 (2006) 257-261
23. Bashshur Z.F., Bazarbachi A., Schakal A., et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 (2006) 1-9